Drugs / PF-06427878
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02855177 | Aug 2016 → Apr 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02410525 | May → Sep 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02391623 | Mar 2015 → Feb 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02237742 | Nov 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02208284 | Aug → Dec 2014 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06427878 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237742 ↗ |
| Action | Inhibit | “selective DGAT2 inhibitor, PF-06427878” PMID 31776293 ↗ Nov 2019 |
| Modality | Small molecule | “Our findings highlight DGAT2 inhibition by a small, potent, selective compound as a potential therapeutic approach for the treatment of NASH.” PMID 31776293 ↗ Nov 2019 |
| Route | Oral | “single oral doses of PF-06427878” NCT02208284 ↗ |
| Target | DGAT2 | “Here, we investigate DGAT2 as a potential therapeutic target using an orally administered, selective DGAT2 inhibitor, PF-06427878.” PMID 31776293 ↗ Nov 2019 |